We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.94%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.45B
AUM Growth
+$719M
Cap. Flow
+$643M
Cap. Flow %
6.8%
Top 10 Hldgs %
29.09%
Holding
237
New
15
Increased
96
Reduced
78
Closed
21

Top Buys

Rank Stock Value
1
ACCD
Accolade Inc
ACCD
+$56.6M
2
RVMD icon
Revolution Medicines
RVMD
+$46M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$43.7M
4
EPIX
ESSA Pharma
EPIX
+$42.4M
5
BDX icon
Becton Dickinson
BDX
+$33.4M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$86.9M
2
HALO icon
Halozyme
HALO
+$47.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$38.1M
4
ESPR
Esperion Therapeutics
ESPR
+$33.9M
5
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$33.3M

Sector Composition

Rank Sector Weight
1 Healthcare 95.93%
2 Industrials 0.88%
3 Technology 0.47%
4 Consumer Discretionary 0.04%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
126
Johnson & Johnson
JNJ
$635B
$6.75M 0.07%
41,100
+13,100
+47% +$2.12M
SGFY
127
DELISTED
Signify Health, Inc.
SGFY
$5.85M 0.06%
+200,000
New +$6.19M
SEER icon
128
Seer Inc
SEER
$108M
$5.51M 0.06%
110,228
+34,892
+46% +$2.04M
OLK
129
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$5.48M 0.06%
+152,137
New +$5.13M
BNTX icon
130
BioNTech
BNTX
$22.6B
$4.97M 0.05%
45,500
+27,500
+153% +$2.92M
SGEN
131
DELISTED
Seagen Inc. Common Stock
SGEN
$4.9M 0.05%
35,300
-11,300
-24% -$1.82M
RARE icon
132
Ultragenyx Pharmaceutical
RARE
$2.65B
$4.67M 0.05%
41,000
– –
LH icon
133
Labcorp
LH
$24.3B
$3.62M 0.04%
16,529
-5,625
-25% -$1.13M
BMRN icon
134
BioMarin Pharmaceuticals
BMRN
$11.5B
$2.79M 0.03%
+37,000
New +$3.02M
CVAC
135
DELISTED
CureVac
CVAC
$2.64M 0.03%
28,900
+11,900
+70% +$1.15M
BHVN
136
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.46M 0.03%
36,000
+23,500
+188% +$1.9M
XNCR icon
137
Xencor
XNCR
$1.44B
$2.29M 0.02%
53,100
+18,000
+51% +$853K
GWPH
138
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.17M 0.02%
10,000
-462,389
-98% -$86.9M
ALLK
139
DELISTED
Allakos
ALLK
$2.12M 0.02%
18,500
– –
RCUS icon
140
Arcus Biosciences
RCUS
$3.57B
$2.11M 0.02%
75,000
+24,000
+47% +$835K
KYNB
141
Kyntra Bio
KYNB
$28.5M
$2.08M 0.02%
2,400
+280
+13% +$298K
APLS
142
DELISTED
Apellis Pharmaceuticals
APLS
$2.06M 0.02%
48,000
– –
ASND icon
143
Ascendis Pharma A/S
ASND
$16.7B
$2M 0.02%
15,500
– –
DRNA
144
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.74M 0.02%
68,000
– –
ACAD icon
145
Acadia Pharmaceuticals
ACAD
$4.25B
$1.7M 0.02%
65,900
+21,000
+47% +$924K
CLLS
146
Cellectis
CLLS
$286M
$1.69M 0.02%
83,500
– –
MRTX
147
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.68M 0.02%
9,800
-2,500
-20% -$495K
KURA icon
148
Kura Oncology
KURA
$922M
$1.64M 0.02%
58,000
– –
SRPT icon
149
Sarepta Therapeutics
SRPT
$1.66B
$1.51M 0.02%
20,300
– –
CAH icon
150
Cardinal Health
CAH
$53.4B
$1.46M 0.02%
+24,000
New +$1.32M
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2021 Portfolio in Review

As of Q1 2021, Bellevue Group held 237 positions worth $9.45B, up 8.2% from $8.73B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $643M of net new capital in Q1 2021, opening 15 new positions and adding to 96 existing holdings. Its largest new stake was ESSA Pharma: 1,825,814 shares worth $53M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $86.9M trimmed.

  • Bellevue Group's largest Q1 2021 buy was ESSA Pharma: 1,825,814 shares worth $53M.
  • Bellevue Group added most to Accolade Inc in Q1 2021, an estimated $56.6M increase.
  • Bellevue Group's biggest Q1 2021 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $86.9M.
  • Bellevue Group fully exited GenMark Diagnostics, Inc in Q1 2021, selling an estimated $38.1M.
  • Bellevue Group's ten largest holdings make up 29% of its $9.45B portfolio in Q1 2021.
  • Bellevue Group opened 15 new positions and closed 21 in Q1 2021.
  • Bellevue Group's portfolio value rose 8.2% quarter-over-quarter to $9.45B.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.